Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Part of paid clinical trials in Palo Alto, California.

Sponsor
Laguna Biotherapeutics, Inc.
Study ID
NCT07573111
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Acute Leukemia
  • Myelodysplastic Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Months - 39 Years
Healthy Volunteers
Not accepted

Interventions

  • QUAIL-100 — BIOLOGICAL
    live, attenuated bacterial therapeutic

Study Details

Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant

Key Dates

First listed
May 7, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Jun 30, 2028
Completion
Mar 31, 2029

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: QUAIL-100 SIngle Ascending Dose
    Single doses of QUAIL-100 at 3x10\^7 to 1x10\^9 CFU

Primary Outcome Measure

Incidence of treatment-emergent adverse events [ Time Frame: 12 weeks after administration of QUAIL-100 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Lucille Packard Children's Hospital of Stanford UniversityPalo AltoCalifornia94304
Noor Akhter
[email protected]
650-725-9709
Orly Klein, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Palo Alto, CA

By research site
Lucille Packard Children's Hospital of Stanford University· Palo Alto, CA

Related Studies